Aflibercept 8 mg for eyes already treated for wet AMD or diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This study looks at how well the higher-dose eye injection aflibercept 8 mg works in people who have already had at least three earlier anti-VEGF injections for wet age-related macular degeneration (wet AMD) or diabetic macular edema (DME). It tests if switching to this stronger dose is safe and effective in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are aged 50 or older for the wet AMD group, or 18 or older for the diabetic macular edema group.
- You have been diagnosed with wet age-related macular degeneration or diabetic macular edema in the study eye.
- You have had at least three prior anti-VEGF injections (like ranibizumab or bevacizumab) in that eye.
- Your doctor has already decided, before this study, to switch you to aflibercept 8 mg as part of your regular care.
- You have not had any anti-VEGF injection in the study eye in the last 28 days, and no steroid eye treatments in the last 3 to 6 months.
- You are not pregnant and do not have an active eye infection or inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Hear when a new nAMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.